KEGG   DRUG: Ozoralizumab
Entry
D09944                      Drug                                   
Name
Ozoralizumab (USAN);
Ozoralizumab (genetical recombination) (JAN);
Nanozora (TN)
Formula
C1682H2608N472O538S12
Exact mass
38410.7875
Mol weight
38434.3245
Class
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
  DG01936  TNF inhibitor
Remark
Therapeutic category: 3999
Product: D09944<JP>
Efficacy
Anti-inflammatory, Anti-TNF-alpha antibody
  Type
Monoclonal antibody, nanobody
Comment
Treatment of inflammation
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04350  TGF-beta signaling pathway
Interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D09944  Ozoralizumab (USAN); Ozoralizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   DG01936  TNF inhibitor
    D09944  Ozoralizumab
Drug classes [BR:br08332]
 Immunological agent
  DG01936  TNF inhibitor
   D09944  Ozoralizumab
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D09944  Ozoralizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D09944  Ozoralizumab (USAN) <JP>
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09944
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09944
Other DBs
CAS: 1167985-17-2
PubChem: 124490626
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system